COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
U.S. counties with more racial and ethnic minority residents, people living in crowded housing and other social vulnerabilities were more likely to become COVID-19 hotspots in June and July, according to a study released by the Centers for Disease Control and Prevention.
The Centers for Disease Control and Prevention updated how it defines 鈥渃lose contact鈥 exposure to an individual infected with the COVID-19 virus to someone within 6 feet of the infected individual for 15 minutes or more cumulatively over a 24-hour period, rather than exposure within 6 feet for at鈥
A study released by the Centers for Disease Control and Prevention estimates 299,028 more deaths than expected occurred in the United States between Jan. 26 and Oct. 3, with 66% attributed to COVID-19.
Other Events This Week Include HHS Webinars on COVID-19 Data Reporting and AHA Leadership Rounds with AHA Chair Dr. Estes
A national training collaborative that aims to provide every person working in a U.S. healthcare facility the foundation for infection control to protect the nation from infectious disease threats, such as COVID-19.
The Food and Drug Administration Oct. 15 removed epinephrine from the lists of drugs authorized for temporary compounding during the COVID-19 public health emergency by outsourcing facilities and state-licensed pharmacies or federal facilities not registered as outsourcing facilities.
The Food and Drug Administration Oct. 15 said it reissued its emergency use authorization for certain, Chinese-manufactured filtering face-piece respirators that lack National Institute for Occupational Safety and Health approval.
The Centers for Medicare & Medicaid Services Oct. 15 said it will incentivize labs to deliver quicker results to patients undergoing COVID-19 diagnostic testing.
The Food and Drug Administration Oct. 13 issued and immediately implemented enforcement policy for modifications to FDA-cleared molecular influenza and RSV tests during the COVID-19 public health emergency to expand access to certain FDA-cleared molecular tests for detecting and identifying flu鈥
Ask Your Representatives to Sign 鈥楧ear Colleague鈥 Letter Urging HHS to Reinstate June COVID-19 Provider Relief Fund Reporting Requirements
Please contact your representatives today and ask them sign on to a 鈥淒ear Colleague鈥 letter to the Department of Health and Human Services (HHS) urging it鈥